AI-generated analysis. Always verify with the original filing.
Atea Pharmaceuticals, Inc. reported fourth quarter and full year 2025 financial results, including a net loss of $44.9 million ($0.57 per share) for Q4 and $158.3 million ($1.94 per share) for the year, with cash and investments of $301.8 million as of December 31, 2025. The company provided updates on its Phase 3 HCV program with topline results expected mid-2026 and year-end 2026, and announced clinical development of AT-587 for HEV starting mid-2026.
Event Type
Disclosure
Mandatory
Variant
8-K
, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),
Financial Statements and Exhibits. (d) Exhibits. 99.1* Press Release, dated March 5, 2026. 104 Cover Page Interactive Data File – the cover page XBRL tags are e